IDO Updates At ASCO: Incyte's Combos With Merck And Bristol Take Center Stage
The immuno-oncology highlight of the upcoming American Society of Clinical Oncology annual meeting will be clinical data for Incyte's epacadostat with Merck's Keytruda as well as data with Bristol's Opdivo.
You may also be interested in...
Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor
The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.
Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.
2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.